Drug Shortage Report for AA-RISEDRONATE DR
Report ID | 213143 |
Drug Identification Number | 02493268 |
Brand name | AA-RISEDRONATE DR |
Common or Proper name | AA_RISEDRONATE dr |
Company Name | AA PHARMA INC |
Market Status | MARKETED |
Active Ingredient(s) | RISEDRONATE SODIUM |
Strength(s) | 35MG |
Dosage form(s) | TABLET (DELAYED-RELEASE) |
Route of administration | ORAL |
Packaging size | 30BTL |
ATC code | M05BA |
ATC description | DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | 2023-12-13 |
Actual start date | |
Estimated end date | 2024-02-20 |
Actual end date | 2024-02-20 |
Shortage status | Resolved |
Updated date | 2024-02-22 |
Company comments | Risedronate DR TAB 35MG, $ tablets /blister is available. |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 1165 CREDITSTONE ROAD VAUGHAN, ONTARIO CANADA L4K 4N7 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v10 | 2024-02-22 | French | Compare |
v9 | 2024-02-22 | English | Compare |
v8 | 2024-02-15 | French | Compare |
v7 | 2024-02-15 | English | Compare |
v6 | 2024-01-31 | English | Compare |
v5 | 2024-01-17 | French | Compare |
v4 | 2024-01-17 | English | Compare |
v3 | 2023-12-14 | English | Compare |
v2 | 2023-12-13 | French | Compare |
v1 | 2023-12-13 | English | Compare |
Showing 1 to 10 of 10